To obtain a new compound of a β2-adrenergic receptor antagonist and also an intermediate of a compound useful for the therapy of asthma, bronchitis, skin diseases, congestive heart insufficiency, glaucoma or the like.
This new compound is expressed by formula I [wherein, Ar is expressed by formula II (wherein, R3 and R4 are H or combined with each other into S, CH2 or the like; R5 is H or a 1-6C alkyl); X is a 1-12C alkylene chain which may be interrupted or ended with S, O or the like; Y is a (substituted) aryl or a cycloalkyl] and is e.g. N-[2-(4-hydroxy-2-oxy-3H-1,3- benzothizaol-7-yl)ethyl]-6-[2-(2,3-dihydro-1H-indenyloxy)]hexanamide. The compound of formula I is produced e.g. by the coupling reaction of an amine with an acid (chloride) in the presence of dicyclohexylcarbodiimide.
DIXON JOHN
INCE FRANCIS
CHESHIRE DAVID RAYULS
BONNERT ROGER VICTOR
